Sunovion Patent-Cliff Exposure & CMS Drug Spending Portfolio
Sunovion (US): 1 reconciled FDA prescription therapies, $74.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2031-01-01 |
| 2024 CMS Total Public Spend | $74.8M |
| 2024 Medicare Part D Spend | $39.6M |
| 2024 Medicaid Spend | $35.1M |
| California HCAI SB 17 Filings | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.